Clinical and Molecular Allergy最新文献

{"title":"Appropriateness in allergic respiratory diseases health care in Italy: definitions and organizational aspects.","authors":"Carlo Lombardi,&nbsp;Eleonora Savi,&nbsp;Maria Teresa Costantino,&nbsp;Enrico Heffler,&nbsp;Manlio Milanese,&nbsp;Giovanni Passalacqua,&nbsp;Giorgio Walter Canonica","doi":"10.1186/s12948-016-0042-3","DOIUrl":"https://doi.org/10.1186/s12948-016-0042-3","url":null,"abstract":"<p><p>In a historical period in which sustainability of the National Health Service is mandatory because of the international economical situation, the limited available resources at national level and the tendency of passing from a \"population medicine\" model towards the concept of \"individualized medicine\", the debate on appropriateness of medical and surgical procedures is of central importance. The choosing wisely campaign, started in United States in 2012 and then spread all over the world, tries to summarize which are the most inappropriate procedures for each medical and surgical speciality; as far as allergic respiratory diseases, the most relevant Italian societies and the American Academy defined the allergological procedures with the highest probability of inappropriateness. In Italy, a recent decree of the Ministry of Health defined a list of more than 200 procedures that will be considered as inappropriate in certain conditions; many of these procedures concern allergology, including allergic respiratory diseases. In this commentary we discuss the above mentioned decree and the concept of appropriateness in the field of allergic respiratory diseases, trying to figure out some practical considerations based on the current health resources available in the field of allergology in Italy. </p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"14 ","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2016-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-016-0042-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34321819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines for the use and interpretation of diagnostic methods in adult food allergy.","authors":"Donatella Macchia,&nbsp;Giovanni Melioli,&nbsp;Valerio Pravettoni,&nbsp;Eleonora Nucera,&nbsp;Marta Piantanida,&nbsp;Marco Caminati,&nbsp;Corrado Campochiaro,&nbsp;Mona-Rita Yacoub,&nbsp;Domenico Schiavino,&nbsp;Roberto Paganelli,&nbsp;Mario Di Gioacchino","doi":"10.1186/s12948-015-0033-9","DOIUrl":"https://doi.org/10.1186/s12948-015-0033-9","url":null,"abstract":"<p><p>Food allergy has an increasing prevalence in the general population and in Italy concerns 8 % of people with allergies. The spectrum of its clinical manifestations ranges from mild symptoms up to potentially fatal anaphylactic shock. A number of patients can be diagnosed easily by the use of first- and second-level procedures (history, skin tests and allergen specific IgE). Patients with complex presentation, such as multiple sensitizations and pollen-food syndromes, frequently require a third-level approach including molecular diagnostics, which enables the design of a component-resolved sensitization profile for each patient. The use of such techniques involves specialists' and experts' skills on the issue to appropriately meet the diagnostic and therapeutic needs of patients. Particularly, educational programs for allergists on the use and interpretation of molecular diagnostics are needed. </p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"13 ","pages":"27"},"PeriodicalIF":0.0,"publicationDate":"2015-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-015-0033-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34065576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers and severe asthma: a critical appraisal.","authors":"Alessandra Chiappori,&nbsp;Laura De Ferrari,&nbsp;Chiara Folli,&nbsp;Pierluigi Mauri,&nbsp;Anna Maria Riccio,&nbsp;Giorgio Walter Canonica","doi":"10.1186/s12948-015-0027-7","DOIUrl":"https://doi.org/10.1186/s12948-015-0027-7","url":null,"abstract":"<p><p>Severe asthma (SA) is a clinically and etiologically heterogeneous respiratory disease which affects among 5-10 % of asthmatic patients. Despite high-dose therapy, a large patients percentage is not fully controlled and has a poor quality of life. In this review, we describe the biomarkers actually known in scientific literature and used in clinical practice for SA assessment and management: neutrophils, eosinophils, periostin, fractional exhaled nitric oxide, exhaled breath condensate and galectins. Moreover, we give an overview on clinical and biological features characterizing severe asthma, paying special attention to the potential use of these ones as reliable markers. We finally underline the need to define different biomarkers panels to select patients affected by severe asthma for specific and personalized therapeutic approach. </p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"13 ","pages":"20"},"PeriodicalIF":0.0,"publicationDate":"2015-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-015-0027-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34226496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are atopy and eosinophilic bronchial inflammation associated with relapsing forms of chronic rhinosinusitis with nasal polyps?","authors":"Mona-Rita Yacoub,&nbsp;Matteo Trimarchi,&nbsp;George Cremona,&nbsp;Sara Dal Farra,&nbsp;Giuseppe Alvise Ramirez,&nbsp;Valentina Canti,&nbsp;Emanuel Della Torre,&nbsp;Mattia Baldini,&nbsp;Patrizia Pignatti,&nbsp;Mario Bussi,&nbsp;Maria Grazia Sabbadini,&nbsp;Angelo A Manfredi,&nbsp;Giselda Colombo","doi":"10.1186/s12948-015-0026-8","DOIUrl":"https://doi.org/10.1186/s12948-015-0026-8","url":null,"abstract":"<p><strong>Background: </strong>The aetiopathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP) is still unknown. The role of atopy and the concept of united airways in such patients are still a matter of debate. In this pilot study we aimed at evaluating the degree of eosinophilic inflammation and the frequency of atopy in a cohort of CRSwNP patients candidate for Functional Endoscopic Sinus Surgery (FESS) and assessing the association between these factors and relapsing forms of CRSwNP.</p><p><strong>Methods: </strong>30 patients (18 men, 12 women) with CRSwNP eligible for FESS were evaluated before and after surgery. Preoperative investigation included: history of previous relapse after FESS, clinical and laboratory allergologic assessment, spirometry, methacholine challenge, blood eosinophilia and determination of the fraction of nitric oxide in exhaled air (FeNO). Nasal fibroendoscopy, spirometry and FeNO determination were also assessed prospectively at 3 and 27 months post-FESS.</p><p><strong>Results: </strong>18/30 subjects were atopic, 6/18 (33 %) were monosensitized, 16/30 (53 %) were asthmatics and 10/30 (33 %) had non steroidalantinflammatory drugs (NSAIDs) hypersensitivity. Twenty-one patients (70 %) were classified as relapsers, 15/18 (83 %) among atopics, 6/12 (50 %) among non atopics (p = 0.05). Among patients with NSAIDs hypersensitivity, 9/10 (90 %) were relapsers. The median IgE concentration was 161.5 UI/mL in relapsers and 79 UI/mL in non-relapsers (ns). The mean FeNO decreased after FESS (43.1-26.6 ppb) in 84 % of patients, but this effect disappeared over time (FeNO = 37.7 ppb at 27 months). Higher levels of FeNO pre-FESS were detected in atopics, and in particular in relapsing ones (median 51.1 ppb vs 22.1, ns). Higher levels of FeNO pre-FESS were detected in asthmatic patients, especially in those who relapsed (median: 67 vs 64.85 ppb in non-relapsed patients, ns). The Tiffeneau Index (FEV1/FVC) was significantly lower in asthmatic relapsers than in non relapsers asthmatics (94.7 ± 11.1 versus 105 ± 5.9-p = 0.04). Patients with asthma and atopy had a major risk of relapse (p = 0.05).</p><p><strong>Conclusion: </strong>In our pilot study, atopy, severe asthma, bronchial inflammation, NSAIDs hypersensitivity and high level of total IgE are possible useful prognostic factors for the proneness to relapse after FESS. The role of allergy in CRSwNP pathogenesis should consequently be given deeper consideration. Allergen specific immunotherapy, combined with anti-IgE therapy, may have an immunomodulatory effect preventing polyps relapse and need to be investigated.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"13 1","pages":"23"},"PeriodicalIF":0.0,"publicationDate":"2015-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-015-0026-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34170459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rituximab in refractory sarcoidosis: a single centre experience.","authors":"Francesco Cinetto,&nbsp;Nicolò Compagno,&nbsp;Riccardo Scarpa,&nbsp;Giacomo Malipiero,&nbsp;Carlo Agostini","doi":"10.1186/s12948-015-0025-9","DOIUrl":"https://doi.org/10.1186/s12948-015-0025-9","url":null,"abstract":"<p><p>Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic refractory disease. Provided that steroids represent the gold standard as a first line treatment, many immune suppressants drugs are currently used in the disease management. However, refractory disease is still a great challenge. Rituximab is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic autoimmune diseases. There are few case reports describing the successful use of Rituximab in refractory sarcoidosis with lung, eye, lymph nodes and skin involvement. In this paper we described three different case reports in which Rituximab has been used to treat refractory sarcoidosis and we reviewed the existing literature. </p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"13 1","pages":"19"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-015-0025-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34140622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Escaping the trap of allergic rhinitis.","authors":"Oliviero Rossi,&nbsp;Ilaria Massaro,&nbsp;Marco Caminati,&nbsp;Cristina Quecchia,&nbsp;Filippo Fassio,&nbsp;Enrico Heffler,&nbsp;Giorgio Walter Canonica","doi":"10.1186/s12948-015-0023-y","DOIUrl":"https://doi.org/10.1186/s12948-015-0023-y","url":null,"abstract":"<p><p>Rhinitis is often the first symptom of allergy but is frequently ignored and classified as a nuisance condition. Ironically it has the greatest socioeconomic burden worldwide caused by its impact on work and on daily life. However, patients appear reticent to seek professional advice, visiting their doctor only when symptoms become 'intolerable' and often when their usual therapy proves ineffective. Clearly, it's time for new and more effective allergic rhinitis treatments. MP29-02 (Dymista®; Meda, Solna, Sweden) is a new class of medication for moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or intranasal corticosteroids is not considered sufficient. MP29-02 is a novel formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP). It benefits not only from the incorporation of two active agents, but also from a novel formulation; its lower viscosity, smaller droplet size, larger volume (137 μl) and wider spray angle ensure optimal coverage of, and retention on the nasal mucosa and contribute to its clinical efficacy. In clinical trials, patients treated with MP29-02 experienced twice the symptom relief as those treated with FP and AZE, who in turn exhibited significantly greater symptom relief than placebo-patients. Indeed, the advantage of MP29-02 over FP was approximately the same as that shown for FP over placebo. The advantage of MP29-02 was particularly evident in those patients for whom nasal congestion is predominant, with MP29-02 providing three times the nasal congestion relief of FP (p = 0.0018) and five times the relief of AZE (p = 0.0001). Moreover, patients treated with MP29-02 achieved each and every response up to a week faster than those treated with FP or AZE alone and in real life 1 in 2 patients reported the perception of well-controlled disease after only 3 days. MP29-02's superiority over FP was also apparent long-term in patients with perennial allergic rhinitis or non-allergic rhinitis, with statistical significance noted from the first day of treatment, with treatment difference maintained for a full year. Taken together, these data suggest that MP29-02 may improve the lives of many of our patients, enabling them to finally escape the allergic rhinitis trap. </p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"13 1","pages":"17"},"PeriodicalIF":0.0,"publicationDate":"2015-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-015-0023-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33964408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TL1A/DR3 axis involvement in the inflammatory cytokine network during pulmonary sarcoidosis.","authors":"M Facco,&nbsp;A Cabrelle,&nbsp;F Calabrese,&nbsp;A Teramo,&nbsp;F Cinetto,&nbsp;S Carraro,&nbsp;V Martini,&nbsp;F Calzetti,&nbsp;N Tamassia,&nbsp;M A Cassatella,&nbsp;G Semenzato,&nbsp;C Agostini","doi":"10.1186/s12948-015-0022-z","DOIUrl":"https://doi.org/10.1186/s12948-015-0022-z","url":null,"abstract":"<p><strong>Background: </strong>TNF-like ligand 1A (TL1A), a recently recognized member of the TNF superfamily, and its death domain receptor 3 (DR3), firstly identified for their relevant role in T lymphocyte homeostasis, are now well-known mediators of several immune-inflammatory diseases, ranging from rheumatoid arthritis to inflammatory bowel diseases to psoriasis, whereas no data are available on their involvement in sarcoidosis, a multisystemic granulomatous disease where a deregulated T helper (Th)1/Th17 response takes place.</p><p><strong>Methods: </strong>In this study, by flow cytometry, real-time PCR, confocal microscopy and immunohistochemistry analyses, TL1A and DR3 were investigated in the pulmonary cells and the peripheral blood of 43 patients affected by sarcoidosis in different phases of the disease (29 patients with active sarcoidosis, 14 with the inactive form) and in 8 control subjects.</p><p><strong>Results: </strong>Our results demonstrated a significant higher expression, both at protein and mRNA levels, of TL1A and DR3 in pulmonary T cells and alveolar macrophages of patients with active sarcoidosis as compared to patients with the inactive form of the disease and to controls. In patients with sarcoidosis TL1A was strongly more expressed in the lung than the blood, i.e., at the site of the involved organ. Additionally, zymography assays showed that TL1A is able to increase the production of matrix metalloproteinase 9 by sarcoid alveolar macrophages characterized, in patients with the active form of the disease, by reduced mRNA levels of the tissue inhibitor of metalloproteinase (TIMP)-1.</p><p><strong>Conclusions: </strong>These data suggest that TL1A/DR3 interactions are part of the extended and complex immune-inflammatory network that characterizes sarcoidosis during its active phase and may contribute to the pathogenesis and to the progression of the disease.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"13 1","pages":"16"},"PeriodicalIF":0.0,"publicationDate":"2015-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-015-0022-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33960957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perianal Crohn's disease and hidradenitis suppurativa: a possible common immunological scenario.","authors":"Francesco Giudici,&nbsp;Laura Maggi,&nbsp;Raffaella Santi,&nbsp;Lorenzo Cosmi,&nbsp;Francesco Annunziato,&nbsp;Gabriella Nesi,&nbsp;Giusi Barra,&nbsp;Gabrio Bassotti,&nbsp;Raffaele De Palma,&nbsp;Francesco Tonelli","doi":"10.1186/s12948-015-0018-8","DOIUrl":"https://doi.org/10.1186/s12948-015-0018-8","url":null,"abstract":"<p><strong>Background: </strong>Crohn's disease (CD) and Hidradenitis suppurativa (HS) are both chronic inflammatory diseases. The pathogenesis of these diseases is multifactorial, due to the interaction of genetic and environmental factors leading to a deregulated local immune response where T lymphocytes play a major role. To the best of our knowledge, no previous study has clarified whether the pathogenetic mechanism of perianal CD and HS is the same. We therefore analyzed the cellular expression pattern and the cytokine repertoire in three patients suffering from both perianal CD and HS.</p><p><strong>Methods: </strong>We evaluated three patients affected by concurrent HS and CD with fistulizing perianal disease. Surgical specimens have been fixed and embedded in paraffin prior to sectioning for histological examination. Inflammatory tissue curettages have been recovered during intervention from perianal fistulas and HS lesions in order to analyze the phenotypic and functional characteristics of infiltrating T cells. In particular we evaluated T cells, by flow cytometry, for cytokine production profile and expression of surface markers. Moreover, analysis of the T cell repertoire was performed by means of spectratyping, in only one patient.</p><p><strong>Results: </strong>A higher frequency of CD4+ CD161+ T lymphocytes has been detected in CD fistulas and in HS lesions than in peripheral blood (PB) samples. In the patient in whom we derived enough cells from the three sources, we found higher frequency of CD4+ IL-17- producing cells in HS lesion and fistula lesion compared to PB. It is noteworthy that the same clonotypes were expanded in this patient in T cells derived from both HS lesion and fistula lesion.</p><p><strong>Conclusion: </strong>The presence of numerous CD4+ CD161+ lymphocytes in fistula and HS lesion curettages suggests that these cells may play a pathogenic role, and candidates CD161 as a possible biological target for medical treatment.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"13 1","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2015-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-015-0018-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33862766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engineered metal based nanoparticles and innate immunity.","authors":"Claudia Petrarca,&nbsp;Emanuela Clemente,&nbsp;Valentina Amato,&nbsp;Paola Pedata,&nbsp;Enrico Sabbioni,&nbsp;Giovanni Bernardini,&nbsp;Ivo Iavicoli,&nbsp;Sara Cortese,&nbsp;Qiao Niu,&nbsp;Takemi Otsuki,&nbsp;Roberto Paganelli,&nbsp;Mario Di Gioacchino","doi":"10.1186/s12948-015-0020-1","DOIUrl":"https://doi.org/10.1186/s12948-015-0020-1","url":null,"abstract":"<p><p>Almost all people in developed countries are exposed to metal nanoparticles (MeNPs) that are used in a large number of applications including medical (for diagnostic and therapeutic purposes). Once inside the body, absorbed by inhalation, contact, ingestion and injection, MeNPs can translocate to tissues and, as any foreign substance, are likely to encounter the innate immunity system that represent a non-specific first line of defense against potential threats to the host. In this review, we will discuss the possible effects of MeNPs on various components of the innate immunity (both specific cells and barriers). Most important is that there are no reports of immune diseases induced by MeNPs exposure: we are operating in a safe area. However, in vitro assays show that MeNPs have some effects on innate immunity, the main being toxicity (both cyto- and genotoxicity) and interference with the activity of various cells through modification of membrane receptors, gene expression and cytokine production. Such effects can have both negative and positive relevant impacts on humans. On the one hand, people exposed to high levels of MeNPs, as workers of industries producing or applying MeNPs, should be monitored for possible health effects. On the other hand, understanding the modality of the effects on immune responses is essential to develop medical applications for MeNPs. Indeed, those MeNPs that are able to stimulate immune cells could be used to develop of new vaccines, promote immunity against tumors and suppress autoimmunity. </p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"13 1","pages":"13"},"PeriodicalIF":0.0,"publicationDate":"2015-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-015-0020-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33909072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Prevalence of positive atopy patch test in an unselected pediatric population.","authors":"Nicola Fuiano,&nbsp;Giuliana Diddi,&nbsp;Maurizio Delvecchio,&nbsp;Cristoforo Incorvaia","doi":"10.1186/s12948-015-0024-x","DOIUrl":"https://doi.org/10.1186/s12948-015-0024-x","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1186/s12948-015-0011-2.]. </p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"13 1","pages":"18"},"PeriodicalIF":0.0,"publicationDate":"2015-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-015-0024-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34271077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}